1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 coun- tries. CA Cancer J Clin 68: 394‑424, 2018.
2. Fearon ER and Vogelsteine B: A genetic model for colorectal tumorigenesis. Cell 61: 759‑767, 1990.
3. Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S and Tabernero J: Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 17: 79‑92, 2017.
4. Goldstein DA, Zeichner SB, Bartnik CM, Neustadter E and Flowers CR: Metastatic colorectal cancer: A systematic review of the value of current therapies. Clin Colorectal Cancer 15: 1-6, 2016.
5. Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin 64: 104‑117, 2014.
6. Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science 331: 1559‑1564, 2011.
7. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J and Bouvier AM: Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244: 254‑259, 2006.
8. Esteller M: Epigenetics in cancer. N Engl J Med 358: 1148‑1159, 2008.
9. Simó‑Riudalbas L and Esteller M: Cancer genomics identifies disrupted epigenetic genes. Hum Genet 133: 713‑725, 2014.
10. Berg M and Søreide K: Genetic and epigenetic traits as biomarkers in colorectal cancer. Int J Mol Sci 12: 9426‑9439, 2011.
11. Baylin SB and Jones PA: Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol 8: pii: a019505, 2016.
12. Feinberg AP: The key role of epigenetics in human disease prevention and mitigation. N Engl J Med 378: 1323‑1334, 2018.
13. Miremadi A, Oestergaard MZ, Pharoah PD and Caldas C: Cancer genetics of epigenetic genes. Hum Mol Genet 16: R28‑R49, 2007.
14. Ferguson‑Smith AC and Greally JM: Epigenetics: Perceptive enzymes. Nature 449: 148‑149, 2007.
15. Søreide K: Chapter 34 ‑ Cancer Epigenetics. In: Handbook of Epigenetics. 2nd Edition. Academic Press, 2017.
16. Nihira NT and Yoshida K: Engagement of DYRK2 in proper control for cell division. Cell Cycle 14: 802‑807, 2015.
17. Taira N, Nihira K, Yamaguchi T, Miki Y and Yoshida K: DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell 25: 725‑738, 2007.
18. Yoshida K: Nuclear trafficking of pro‑apoptotic kinases in response to DNA damage. Trends Mol Med 14: 305‑313, 2008.
19. Taira N, Mimoto R, Kurata M, Yamaguchi T, Kitagawa M, Miki Y and Yoshida K: DYRK2 priming phosphorylation of c‑Jun and c‑Myc modulates cell cycle progression in human cancer cells. J Clin Invest 122: 859‑872, 2012.
20. Maddika S and Chen J: Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase. Nat Cell Biol 11: 409‑419, 2009.
21. Jung HY, Wang X, Jun S and Park JI: Dyrk2‑associated EDD‑DDB1‑VprBP E3 ligase inhibits telomerase by TERT degradation. J Biol Chem 288: 7252‑7262, 2013.
22. Mimoto R, Taira N, Takahashi H, Yamaguchi T, Okabe M, Uchida K Miki Y and Yoshida K: DYRK2 controls the epithe- lial‑mesenchymal transition in breast cancer by degrading Snail. Cancer Lett 339: 214‑225, 2013.
23. Yamashita S, Chujo M, Moroga T, Anami K, Tokuishi K, Miyawaki M, Kawano Y, Takeno S, Yamamoto S and Kawahara K: DYRK2 expression may be a predictive marker for chemotherapy in non‑small cell lung cancer. Anticancer Res 29: 2753‑2757, 2009.
24. Zhang X, Xu P, Ni W, Fan H, Xu J, Chen Y, Huang W, Lu S, Liang L, Liu J, et al: Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma. Pathol Res Pract 212: 162‑170, 2016.
25. Yan H, Hu K, Wu W, Li Y, Tian H, Chu Z, Koeffler HP and Yin D: Low expression of dyrk2 (dual specificity tyrosine phos- phorylation regulated Kinase 2) correlates with poor prognosis in colorectal cancer. PLoS One 11: e0159954, 2016.
26. Ito D, Yogosawa S, Mimoto R, Hirooka S, Horiuchi T, Eto K, Yanaga K and Yoshida K: Dual‑specificity tyrosine‑regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer. Cancer Sci 108: 1565‑1573, 2017.
27. Livak KJ and Schmittgen TD: Analysis of relative gene expres- sion data using real‑time quantitative PCR and the 2(‑Delta Delta C(T)) method. Methods 25: 402‑408, 2001.
28. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al: AJCC Cancer Staging Manual, 8th edition. Springer, New York, 2017.
29. Komashko VM and Farnham PJ: 5‑azacytidine treatment reor- ganizes genomic histone modification patterns. Epigenetics 5: 229‑240, 2010.
30. Kim M, Miyamoto S, Sugie S, Yasui Y, Ishigamori‑Suzuki R, Murakami A, Nakagama H and Tanaka T: A tobacco‑specific carcinogen, NNK, enhances AOM/DSS‑induced colon carcino- genesis in male A/J mice. In Vivo 22: 557‑563, 2008.
31. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S and Mori H: A novel inflammation‑related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 94: 965‑973, 2003.
32. Tanaka T, Yasui Y, Tanaka M, Tanaka T, Oyama T and Rahman KM: Melatonin suppresses AOM/DSS‑induced large bowel oncogenesis in rats. Chem Biol Interact 177: 128‑136, 2009.
33. Yasui Y, Hosokawa M, Mikami N, Miyashita K and Tanaka T: Dietary astaxanthin inhibits colitis and colitis‑associated colon carcinogenesis in mice via modulation of the inflammatory cyto- kines. Chem Biol Interact 193: 79‑87, 2011.
34. Miyoshi N, Nagasawa T, Mabuchi R, Yasui Y, Wakabayashi K, Tanaka T and Ohshima H: Chemoprevention of azoxy- methane/dextran sodium sulfate‑induced mouse colon carcinogenesis by freeze‑dried yam sanyaku and its constituent diosgenin. Cancer Prev Res (Phila) 4: 924‑934, 2011.
35. Mimoto R, Imawari Y, Hirooka S, Takeyama H and Yoshida K: Impairment of DYRK2 augments stem‑like traits by promoting KLF4 expression in breast cancer. Oncogene 36: 1862‑1872, 2017.
36. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar‑Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 20: 2429‑2440, 2002.
37. Gnyszka A, Jastrzebski Z and Flis S: DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res 33: 2989‑2996, 2013.
38. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, et al: Transient low doses of DNA‑demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21: 430‑446, 2012.
39. Probst AV, Dunleavy E and Almouzni G: Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell Biol 10: 192‑206, 2009.
40. He S, Wang F, Yang L, Guo C, Wan R, Ke A, Xu L, Hu G, Xu X Shen J and Wang X: Expression of DNMT1 and DNMT3a are regulated by GLI1 in human pancreatic cancer. PLoS One 6: e27684, 2011.
41. Rajendran G, Shanmuganandam K, Bendre A, Muzumdar D, Goel A and Shiras A: Epigenetic regulation of DNA methyltrans- ferases: DNMT1 and DNMT3B in gliomas. J Neurooncol 104: 483‑494, 2011.
42. Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y and Sasaki H: Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 97: 1172‑1179, 2001.
43. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA and Jones PA: The human DNA methyltransferases (DNMTs) 1, 3a and 3b: Coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 27: 2291‑2298, 1999.
44. Lee YC, Lee YL, Chuang JP and Lee JC: Differences in survival between colon and rectal cancer from SEER data. PLoS One 8: e78709, 2013.
論文の公開元へ
